MA56513A - Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie - Google Patents
Dégradation de protéine ciblée de parp14 pour une utilisation en thérapieInfo
- Publication number
- MA56513A MA56513A MA056513A MA56513A MA56513A MA 56513 A MA56513 A MA 56513A MA 056513 A MA056513 A MA 056513A MA 56513 A MA56513 A MA 56513A MA 56513 A MA56513 A MA 56513A
- Authority
- MA
- Morocco
- Prior art keywords
- parp14
- therapy
- protein degradation
- targeted protein
- targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863357P | 2019-06-19 | 2019-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56513A true MA56513A (fr) | 2022-04-27 |
Family
ID=71527971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056513A MA56513A (fr) | 2019-06-19 | 2020-06-18 | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220388985A1 (fr) |
| EP (1) | EP3986887A1 (fr) |
| JP (1) | JP2022537349A (fr) |
| KR (1) | KR20220024098A (fr) |
| CN (1) | CN114206853A (fr) |
| AU (1) | AU2020296063A1 (fr) |
| BR (1) | BR112021025645A2 (fr) |
| CA (1) | CA3142002A1 (fr) |
| MA (1) | MA56513A (fr) |
| SG (1) | SG11202112980TA (fr) |
| WO (1) | WO2020257416A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI813611B (zh) | 2017-12-21 | 2023-09-01 | 美商律幫治療股份有限公司 | 作為parp14抑制劑之喹唑啉酮 |
| AU2022205670A1 (en) * | 2021-01-08 | 2023-07-13 | The Board Of Regents Of The University Of Texas System | Nimbolide analogs and methods of use thereof |
| JP2024505228A (ja) * | 2021-01-29 | 2024-02-05 | ライボン・セラピューティクス・インコーポレイテッド | 炎症性疾患を処置する方法 |
| CN114890989B (zh) * | 2022-05-25 | 2024-03-22 | 广东晨康生物科技有限公司 | 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用 |
| WO2024026081A1 (fr) | 2022-07-29 | 2024-02-01 | Ribon Therapeutics, Inc. | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
| US20240051946A1 (en) | 2022-07-29 | 2024-02-15 | Ribon Therapeutics, Inc. | Targeted protein degradation of parp14 for use in therapy |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3134403T (lt) * | 2014-04-23 | 2020-05-11 | Incyte Corporation | 1h-pirolo[2,3-c]piridin-7(6h)-onai ir pirazolo[3,4-c]piridin-7(6h)-onai, kaip bet baltymų inhibitoriai |
| WO2017197056A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
| US20210154184A1 (en) * | 2017-07-12 | 2021-05-27 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
-
2020
- 2020-06-18 BR BR112021025645A patent/BR112021025645A2/pt unknown
- 2020-06-18 CN CN202080044704.2A patent/CN114206853A/zh active Pending
- 2020-06-18 CA CA3142002A patent/CA3142002A1/fr active Pending
- 2020-06-18 AU AU2020296063A patent/AU2020296063A1/en active Pending
- 2020-06-18 US US17/619,459 patent/US20220388985A1/en active Pending
- 2020-06-18 EP EP20737701.1A patent/EP3986887A1/fr active Pending
- 2020-06-18 WO PCT/US2020/038377 patent/WO2020257416A1/fr unknown
- 2020-06-18 KR KR1020217041538A patent/KR20220024098A/ko unknown
- 2020-06-18 JP JP2021575326A patent/JP2022537349A/ja active Pending
- 2020-06-18 MA MA056513A patent/MA56513A/fr unknown
- 2020-06-18 SG SG11202112980TA patent/SG11202112980TA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3986887A1 (fr) | 2022-04-27 |
| BR112021025645A2 (pt) | 2022-02-01 |
| US20220388985A1 (en) | 2022-12-08 |
| WO2020257416A1 (fr) | 2020-12-24 |
| JP2022537349A (ja) | 2022-08-25 |
| AU2020296063A1 (en) | 2021-12-23 |
| KR20220024098A (ko) | 2022-03-03 |
| SG11202112980TA (en) | 2021-12-30 |
| CN114206853A (zh) | 2022-03-18 |
| CA3142002A1 (fr) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56513A (fr) | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie | |
| MA55511A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
| MA53921A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
| DK3681500T3 (da) | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi | |
| EA201790192A1 (ru) | СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА | |
| IL277444A (en) | Ionic liquid preparations for the treatment of rosacea | |
| EA202091865A1 (ru) | Композиции и способы для снижения экспрессии tau | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| DK3743420T3 (da) | Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase | |
| DK3290441T3 (da) | Rgma-bindingsprotein og anvendelse deraf | |
| DK3532059T3 (da) | Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer | |
| DK3737402T5 (da) | Modificeret protein | |
| MA43587A (fr) | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 | |
| MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
| BR112019007426A2 (pt) | método para reduzir a proteinúria em um sujeito humano que sofre de igan. | |
| MA50383A (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| IL288090A (en) | Expression of antigen-binding proteins in the nervous system | |
| MA55467A (fr) | Utilisations thérapeutiques de dulaglutide | |
| MA55016A (fr) | Utilisation du spiropidion | |
| DK3898985T3 (da) | Proteinekspression i tandem | |
| UA41274S (uk) | Масажер | |
| FR3037228B1 (fr) | Ancillaire pour chirurgie ligamentaire de la cheville | |
| ES1238331Y (es) | Unidad móvil de hidromasaje |